venous thromboembolic
- Health
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
Ingelheim, Germany: No approved therapy for the treatment and prevention of venous thromboembolic events in children until now Current standard…
Read More »